1. bookTom 49 (2015): Zeszyt 2 (June 2015)
Informacje o czasopiśmie
License
Format
Czasopismo
eISSN
1581-3207
Pierwsze wydanie
30 Apr 2007
Częstotliwość wydawania
4 razy w roku
Języki
Angielski
Open Access

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients

Data publikacji: 25 Mar 2015
Tom & Zeszyt: Tom 49 (2015) - Zeszyt 2 (June 2015)
Zakres stron: 173 - 180
Otrzymano: 24 Sep 2014
Przyjęty: 15 Oct 2014
Informacje o czasopiśmie
License
Format
Czasopismo
eISSN
1581-3207
Pierwsze wydanie
30 Apr 2007
Częstotliwość wydawania
4 razy w roku
Języki
Angielski

1 . Califano R, Abidin AZ, Peck R, Faivre-Finn C, Lorigan P. Management of Small Cell Lung Cancer. Recent developments for optimal care. Drugs 2012; 72: 471-90. 10.2165/11597640-000000000-0000022356287Search in Google Scholar

2 . Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia. Risks, consequences, and new directions for its management. Cancer 2004; 100: 228-37. 10.1002/cncr.1188214716755Search in Google Scholar

3 . de Naurois J, Novitzky-Basso I, Gill MJ, Marti Marti F, Cullen MH, Roila F, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol 2010; 21(Suppl 5): v252-6. 10.1093/annonc/mdq19620555092Search in Google Scholar

4 . Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 2014; 90: 190-9. 10.1016/j.critrevonc.2013.12.00624434034Search in Google Scholar

5 . Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011; 11: 1471-2407. 10.1186/1471-2407-11-404320309821943360Search in Google Scholar

6 . Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnely JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors. Eur J Cancer 2011; 47: 8-32. 10.1016/j.ejca.2010.10.01321095116Search in Google Scholar

7 . Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-205. 10.1200/JCO.2006.06.445116682719Search in Google Scholar

8 . National Comprehensive Cancer Network. NCCN Guidelines Version 2.2013. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#myeloid_growthMyeloid growth factors. Accessed 11 September 2013. Search in Google Scholar

9 . Crawford J, Caserta C, Roila F. Haematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol 2010; 21(Suppl 5): v248-51.10.1093/annonc/mdq19520555091Search in Google Scholar

10. Krogh-Madsen M, Honoré Hansen S, Hartvig Honoré P. Simultaneous determination of cytosine arabinoside, daunorubicin and etoposide in human plasma. J Chromatogr B 2010; 878: 1967-72.10.1016/j.jchromb.2010.05.03120542475Search in Google Scholar

11. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10: 282-91.10.1200/JCO.1992.10.2.2821310103Search in Google Scholar

12. Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas Ph, et al. Randomized comparison of etoposide-cisplatin vs. etoposidecarboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group Study. Ann Oncol 1994; 5: 601-7.10.1093/oxfordjournals.annonc.a0589317993835Search in Google Scholar

13. Kosmidis PA, Samantas E, Fountzilas G, Pavlidis N, Apostolopoulou F, Skarlos D. Cisplatin/etoposide versus carboplatin/ etoposide chemotherapy and irradiation in small cell lung cancer randomized phase II study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol 1994; 21(Suppl 6): 23-30.Search in Google Scholar

14. Miller AA, Herndon JE 2nd, Hollis DR, Ellerton J, Langleben A, Richards F 2nd, et al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1995; 13: 1871-9.10.1200/JCO.1995.13.8.18717636529Search in Google Scholar

15. Pujol JL, Daurès JP, Rivière A, Quoix E, Westeel V, Quantin X, et al. Etoposide plus cisplatin with or without the combination of 4’-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001; 93: 300-8.10.1093/jnci/93.4.30011181777Search in Google Scholar

16. Quo ix E, Breton JL, Daniel C, Jacoulet P, Debieuvre D, Paillot N, et al. Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study. Ann Oncol 2001; 12: 957-62.10.1023/A:1011171722175Search in Google Scholar

17. Schiller JH, Adak S, Cella D, DeVore RF 3rd, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 2114-22.10.1200/JCO.2001.19.8.211411304763Search in Google Scholar

18. Hanna N, Bunn Jr. PA, Langer C, Einhorn L, Guthrie T Jr, Beck T, et al. Randomized phase III trial comparing irinotekan/cisplatin with etoposide/ cisplatin in patients with previously untreated extensive stage disease smallcell lung cancer. J Clin Oncol 20 06; 24: 2038-43.10.1200/JCO.2005.04.859516648503Search in Google Scholar

19. Sch mittel A, Fischer von Weikersthal L, Sebastian M, Martus P, Schulze K, Hortig P, et al. A randomized phase II trial of irinotekan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol 2006; 17: 663-7.10.1093/annonc/mdj13716423848Search in Google Scholar

20. Heigener DF, Manegold C, Jäger E, Saal JG, Zuna I, Gatzemeier U. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in “extensive disease” stage. Am J Clin Oncol 2009; 32: 61-4.10.1097/COC.0b013e31817be95419194127Search in Google Scholar

21. Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009; 27: 2530-5.10.1200/JCO.2008.20.1061268485519349543Search in Google Scholar

22. Zatloukal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 2010; 21: 1810-6.10.1093/annonc/mdq03620231298Search in Google Scholar

23. Maas HAAM, Janssen-Heijnen MLG, Olde Rikkert MGM, Machteld Wymenga AN. Comprehensive Geriatric assessment and its clinical impact in oncology. Eur J Cancer 2007; 43: 2161-9.10.1016/j.ejca.2007.08.00217855074Search in Google Scholar

24. Craw ford J, Glaspy JA, Stoller RG, Tomita DK, Vincent ME, McGuire BW, et al. Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther 2005; 3: 36-46.10.3816/SCT.2005.n.02318632435Search in Google Scholar

25. Clarke’s analysis of drugs and poisons. Moffat AC, Osselton MD, Widdop B, Watts J, editors. Available from: http://www.medicinescomplete.com/mc/clarke/current/CLK0691.htm?q=etoposide&t=search&ss=text&p=1#_hit. Accessed 19 September 2013.Search in Google Scholar

26. López-Pousa A, Rifà J, Casas de Tejerina A, González-Larriba JL, Iglesias C, Gasquet JA, et al. Risk assessment model for first-cycle chemotherapyinduced neutropenia in patients with solid tumors. Eur J Cancer Care 2010; 19: 648-55.10.1111/j.1365-2354.2009.01121.x308242720088918Search in Google Scholar

27. Lyman GH , Lyman CH, Agboola O. Risk models for predicting chemotherapyinduced neutropenia. Oncologist 2005; 10: 427-37.10.1634/theoncologist.10-6-42715967836Search in Google Scholar

28. Režonja R, Knez L, Čufer T, Mrhar A. Oral treatment with etoposide in small cell lung cancer - dilemmas and solutions. Radiol Oncol 2013; 47: 1-13.10.2478/raon-2013-0008357382823450046Search in Google Scholar

Polecane artykuły z Trend MD

Zaplanuj zdalną konferencję ze Sciendo